“Flexible Dosing of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: Initial Results From the Real-World–Simulating Expanded Access Protocol Study, JADE REAL”. 2025. SKIN The Journal of Cutaneous Medicine 9 (6): s618. https://doi.org/10.25251/t4rkzz84.